Among non-viral vectors, the cationic polymer chitosan has gained attention as a gene delivery system. We hypothesized that the addition of casein into the nanoparticle’s structure would facilitate a proper gene transfer. The work herein presented aimed to optimize the production method of chitosan-casein nanoparticles (ChiCas NPs) and to test their ability as a gene delivery system. ChiCas NPs formulation optimization was carried out by analyzing several characteristics such as NP size, zeta potential, and chitosan and casein incorporation efficacy. The best formulation developed presented small and homogenous particle size (around 335 nm) and positive zeta potential (≈ + 38 mV), and showed to be stable for 34 weeks both, at 4°C and 20°C. The particles were further used to entrap or to adsorb DNA and form NPs-DNA complexes. In vitro transfection studies, carried out in COS-7 cells, suggested a low transfection efficiency of the different NPs:DNA ratios tested, comparatively to the positive control. Nonetheless, we could observe that the complexes with larger sizes presented better transfection results than those with smaller diameters. To conclude, ChiCas NPs have great technological potential since the preparation process is very simple, and the DNA incorporation efficacy is very high and shows to be physically very stable. The NPs:DNA ratio still needs to be optimized with the aim of achieving better transfection results and being able to anticipate a high gene expression on DNA-based vaccination studies.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
Mansouri S, Lavigne P, Corsi K, Benderdour M, Beaumont E, Fernandes JC. Chitosan-DNA nanoparticles as non-viral vectors in gene therapy: strategies to improve transfection efficacy. Eur J Pharm Biopharm. 2004;57(1):1–8. https://doi.org/10.1016/S0939-6411(03)00155-3.
Jesus S, Soares E, Borchard G, Borges O. Poly-ϵ-caprolactone/chitosan nanoparticles provide strong adjuvant effect for hepatitis B antigen. Nanomedicine. 2017;12(19):2335–48.
Park J, Kim WJ. Current status of gene delivery: spotlight on nanomaterial-polymer hybrids. J Drug Target. 2012;20(8):648–66. https://doi.org/10.3109/1061186X.2012.704634.
Nitta SK, Numata K. Biopolymer-based nanoparticles for drug/gene delivery and tissue engineering. Int J Mol Sci. 2013;14(1):1629–54. https://doi.org/10.3390/ijms14011629.
Garaiova Z, Strand SP, Reitan NK, Lelu S, Storset SO, Berg K, et al. Cellular uptake of DNA-chitosan nanoparticles: the role of clathrin- and caveolae-mediated pathways. Int J Biol Macromol. 2012;51(5):1043–51.
Lebre F, Borchard G, Faneca H, De Lima MCP, Borges O. Intranasal administration of novel chitosan nanoparticle/DNA complexes induces antibody response to hepatitis B surface antigen in mice. Mol Pharm. 2016;13(2):472–82.
Thomas M, Klibanov AM. Non-viral gene therapy: polycation-mediated DNA delivery. Appl Microbiol Biotechnol. 2003;62(1):27–34. https://doi.org/10.1007/s00253-003-1321-8.
Morille M, Passirani C, Vonarbourg A, Clavreul A, Benoit JP. Progress in developing cationic vectors for non-viral systemic gene therapy against cancer. Biomaterials. 2008;29(24–25):3477–96.
Kay MA. State-of-the-art gene-based therapies: the road ahead. Nat Rev Genet. 2011;12(5):316–28. https://doi.org/10.1038/nrg2971.
Paiva D, Ivanova G, Pereira MD, Rocha S. Chitosan conjugates for DNA delivery. Phys Chem Chem Phys. 2013;15:11893–9. https://doi.org/10.1039/c3cp51215k.
Baldrick P. The safety of chitosan as a pharmaceutical excipient. Regul Toxicol Pharmacol. 2010;56(3):290–9. https://doi.org/10.1016/j.yrtph.2009.09.015.
Duceppe N, Tabrizian M. Advances in using chitosan-based nanoparticles for in vitro and in vivo drug and gene delivery. Expert Opin Drug Deliv. 2010;7(10):1191–207.
Hejazi R, Amiji M. Chitosan-based gastrointestinal delivery systems. J Control Release. 2003;89(2):151–65. https://doi.org/10.1016/S0168-3659(03)00126-3.
Agnihotri SA, Mallikarjuna NN, Aminabhavi TM. Recent advances on chitosan-based micro- and nanoparticles in drug delivery. J Control Release. 2004;100(1):5–28. https://doi.org/10.1016/j.jconrel.2004.08.010.
Borges O, Borchard G, de Sousa A, Junginger HE, Cordeiro-da-Silva A. Induction of lymphocytes activated marker CD69 following exposure to chitosan and alginate biopolymers. Int J Pharm. 2007;337(1–2):254–64.
Anal AK, Tobiassen A, Flanagan J, Singh H. Preparation and characterization of nanoparticles formed by chitosan-caseinate interactions. Colloids Surf B Biointerfaces. 2008;64(1):104–10. https://doi.org/10.1016/j.colsurfb.2008.01.010.
Lebre F, Bento D, Jesus S, Borges O. Chitosan-based nanoparticles as a hepatitis B antigen delivery system. In: Methods in Enzymology, vol. 509. 1st ed. Amsterdam: Elsevier Inc; 2012. p. 127–42.
Mao HQ, Roy K, Troung-Le VL, Janes KA, Lin KY, Wang Y, et al. Chitosan-DNA nanoparticles as gene carriers: synthesis, characterization and transfection efficiency. J Control Release. 2001;70(3):399–421. https://doi.org/10.1016/S0168-3659(00)00361-8.
Gao Y, Xu Z, Chen S, Gu W, Chen L, Li Y. Arginine-chitosan/DNA self-assemble nanoparticles for gene delivery: in vitro characteristics and transfection efficiency. Int J Pharm. 2008;359(1–2):241–6.
Elzoghby AO, Abo El-Fotoh WS, Elgindy NA. Casein-based formulations as promising controlled release drug delivery systems. J Control Release. 2011;153(3):206–16. https://doi.org/10.1016/j.jconrel.2011.02.010.
Elzoghby AO, Samy WM, Elgindy NA. Protein-based nanocarriers as promising drug and gene delivery systems. J Control Release. 2012;161(1):38–49. https://doi.org/10.1016/j.jconrel.2012.04.036.
Soto ER, O’Connell O, Dikengil F, Peters PJ, Clapham PR, Ostroff GR. Targeted delivery of glucan particle encapsulated gallium nanoparticles inhibits HIV growth in human macrophages. J Drug Deliv. 2016;2016(8520629):1–8.
Soto ER, Caras AC, Kut LC, Castle MK, Ostroff GR. Glucan particles for macrophage targeted delivery of nanoparticles. J Drug Deliv. 2012;2012:1–13. https://doi.org/10.1155/2012/143524.
Tesz GJ, Aouadi M, Prot M, Nicoloro SM, Boutet E, Amano SU, et al. Glucan particles for selective delivery of siRNA to phagocytic cells in mice. Biochem J. 2011;436(2):351–62. https://doi.org/10.1042/BJ20110352.
Mendelovits A, Prat T, Gonen Y, Rytwoa G. Improved colorimetric determination of chitosan concentrations by dye binding. Appl Spectrosc. 2012;66(8):979–82. https://doi.org/10.1366/12-06591a.
Wischke C, Borchert HH. Increased sensitivity of chitosan determination by a dye binding method. Carbohydr Res. 2006;341(18):2978–9. https://doi.org/10.1016/j.carres.2006.10.012.
Muzzarelli RA. Colorimetric determination of chitosan. Anal Biochem. 1998;260(2):255–7. https://doi.org/10.1006/abio.1998.2705.
Cordeiro RA, Santo D, Farinha D, Serra A, Faneca H, Coelho JFJ. High transfection efficiency promoted by tailor-made cationic tri-block copolymer-based nanoparticles. Acta Biomater. 2017;47:113–23. https://doi.org/10.1016/j.actbio.2016.10.015.
Jesus S, Borchard G, Borges O. Freeze dried chitosan/poly-ε-caprolactone and poly-ε-caprolactone nanoparticles: evaluation of their potential as DNA and antigen delivery systems. J Genet Syndr Gene Ther. 2013;4(7):1–11.
Nasti A, Zaki NM, De Leonardis P, Ungphaiboon S, Sansongsak P, Rimoli MG, et al. Chitosan/TPP and chitosan/TPP-hyaluronic acid nanoparticles: systematic optimisation of the preparative process and preliminary biological evaluation. Pharm Res. 2009;26(8):1918–30. https://doi.org/10.1007/s11095-009-9908-0.
Fernández-Urrusuno R, Calvo P, Remuñán-López C, Vila-Jato JL, Alonso MJ. Enhancement of nasal absorption of insulin using chitosan nanoparticles. Pharm Res. 1999;16:1576–81. https://doi.org/10.1023/A:1018908705446.
Senior J, Trimble K, Maskiewicz R. Interaction of positively-charged liposomes with blood: implications for their application in vivo. BBA - Biomembr. 1991;1070(1):173–9.
Sarah P, Clarke, B. Development of hierarchical magnetic nanocomposite materials for biomedical applications thesis submitted for the degree of doctor of Philosophy. 2013, DOI: https://doi.org/10.1080/14789949.2013.862292.
Strand SP, Lelu S, Reitan NK, de Lange Davies C, Artursson P, Vårum KM. Molecular design of chitosan gene delivery systems with an optimized balance between polyplex stability and polyplex unpacking. Biomaterials. 2010;31(5):975–87. https://doi.org/10.1016/j.biomaterials.2009.09.102.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Panão Costa, J., Carvalho, S., Jesus, S. et al. Optimization of Chitosan-α-casein Nanoparticles for Improved Gene Delivery: Characterization, Stability, and Transfection Efficiency. AAPS PharmSciTech 20, 132 (2019). https://doi.org/10.1208/s12249-019-1342-y
- chitosan nanoparticles
- gene delivery system
- DNA vaccine